Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Chubb Ltd (CB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Chubb Ltd — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.13 (market cap $29.60B), while Chubb Ltd trades at $347.57 (market cap $133.90B). The key difference: Chubb Ltd is far larger — about 4.5× Alnylam Pharmaceuticals, Inc.'s market cap, and Chubb Ltd pays a 1.18% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | CB | |
|---|---|---|
Market Cap | $29.60B | $133.90B |
Sector | Health | Financials |
52-Week High | $491.22 | $363.50 |
52-Week Low | $205.48 | $268.20 |
Enterprise Value | $27.56B | $154.74B |
Dividend Yield | — | 1.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $216.98, down 1.01% with bearish technical signals. The company shows strong revenue growth from $1.0B in 2022 to $3.7B in 2025, turning profitable with $314M net income. However, recent Q2 2026 earnings missed expectations, and multiple law firms are investigating potential securities fraud. Analyst consensus remains bullish with a $370.07 price target despite recent volatility.
The stock faces near-term pressure from legal investigations and earnings volatility, but strong fundamentals and analyst support suggest long-term potential. Key risks include legal outcomes and execution on growth targets, while the 71% upside to consensus target offers opportunity if the company can maintain its revenue trajectory.
Chubb Limited (CB) trades at $348.3, down 0.57% on the day, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 12.3, net income margin of 17.96%, and consistent earnings beats in recent quarters. Recent news highlights partnerships and leadership appointments, supporting growth prospects. Cash flow trends indicate stable operations, with 2026 net cash flow projected at $382 million.
The outlook for CB is positive, driven by disciplined underwriting, premium growth, and rising investment income. Risks include competitive pressures and macroeconomic volatility. Analysts maintain a buy consensus with a $366.83 price target, suggesting upside potential. The stock presents a value opportunity with solid dividend income, though investors should monitor underwriting performance and market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Chubb Ltd
ACE acquired Chubb in the first quarter of 2016 and assumed the Chubb name. The combination makes the new Chubb one of the largest domestic property and casualty insurers, with operations in 54 countries spanning commercial and personal P&C insurance, reinsurance, and life insurance.
Read more on CB →
